Navigation Links
Substance tackles skin cancer from 2 sides
Date:11/2/2008

By playing it safe and using a two-pronged attack, a novel designer molecule fights malignant melanoma. It was created and tested by an international team of researchers led by the University of Bonn. On the one hand, the substance is similar to components of viruses and in this way alerts the immune system. The body's own defences are also strengthened against cancer cells in this process. At the same time, the novel molecule also puts pressure on the tumour in a different way. It switches off a specific gene in the malignant cells, thus driving them to suicide. With mice suffering from cancer, the researchers have thus been able to fight metastases in the lung. In Nature Medicine's November issue they report about this promising strategy. This article is available online from November 2nd 6 p.m. GMT onwards (doi: 10.1038/nm.1887).

For their research project, the scientists drew on the latest insights into biology's box of tricks. A close relative of the nuclear DNA, known as RNA, served them as therapy. It has only been known for a few years that small RNA molecules can basically be used to target certain genes and switch them off. This effect is called RNA interference; the Americans Craig Mellow and Andrew Fire were awarded the Nobel Prize in 2006 for its discovery.

'We used this method in order to drive the tumour cells to suicide,' the Bonn dermatology researcher Professor Thomas Tting explains. Every single body cell is equipped with a corresponding suicide programme. It is activated, for example, if the cell becomes malignant. It dies before it can do any more harm. 'But in tumours a gene is active that suppresses this suicide programme,' Professor Tting, who is head of the Experimental Dermatology Laboratory, explains. 'We have pinpointed this gene and switched it off by using RNA interference.'

At the same time the researchers also crept up on cancer by another route: 'We basically "disguised" our RNA,' Professor Gunt
'/>"/>

Contact: Professor Thomas Tting
Thomas.Tueting@ukb.uni-bonn.de
49-022-828-719-257
University of Bonn
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Mailman School of Public Health study examines link between racial discrimination and substance use
2. National Quality Forum Issues First Consensus Standards for the Treatment of Substance Use Conditions
3. Inflammatory Substance May Boost Eye Trouble
4. Research examines connection between substance abuse and violence
5. L.A. Author, TV Personality and Substance Abuse Specialist Discusses Struggle to Break Bad-girl Syndrome Oct. 26-28 in Baltimore
6. Gauging parent knowledge about teens substance use
7. Substance abuse practitioners ask what is recovery?
8. One-Third of Popular Songs Refer to Substance Abuse
9. AAPM statement on DEA ruling allowing multiple prescriptions for controlled substances
10. Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility
11. PSU $5.7 million grant to help families and youth avoid substance abuse, behavior problems

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...treatment equals a $41,000 pay raise, researchers ...s) -- Psychological therapy may be much more effec...r winning a lottery prize, suggests an English stu... people who provided information about their menta...ess from a $1,329 course of therapy was so signifi...
(Date:11/29/2009)...nal healthcare,s uncertain future and rising costs...are. Affordable Acupuncture Scottsdale answers the... 29, 2009 -- Affordable Acupuncture, LLC opened in...en met with enthusiasm and gratitude. Its increasi...to two things, need and cost. "As far as I&r...
(Date:11/28/2009)...to consider change after 30-minute psychosocial in... 27 (HealthDay News) -- A program that gets persis...p their dangerous behavior may lead to significant... , The new study included 184 men and women wit...who were randomly assigned to one of two intervent...
(Date:11/27/2009)...27 GSI Group Inc. (Pink ...sion technology products and semiconductor systems...mpany,s shareholders has been scheduled for Friday...eting will be announced in due course. As previou...notice from Stephen Bershad, a holder of greater t...
(Date:11/27/2009)...swire-USNewswire/ -- Considered a highly risky and..., solid organ transplantation is now a life-saving...men and women who gathered at the Winspear Opera H...rom medical centers around the world to celebrate ... Institute (BRTI), one of the pioneers of solid or...
Breaking Medicine News(10 mins):Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:Affordable Acupuncture Greeted with Open Arms by Scottsdale and Phoenix Communities 2Health News:Drunk Drivers May Respond to Brief Motivational Interview 2Health News:GSI Group Calls Shareholders Meeting 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3
... an associate professor of medicine at Boston Univ...an in the General Internal Medicine Department at ...director of the Substance Abuse Prevention and Tre...esented at the American Association for the Treatm...
...f of patients, study found , TUESDAY, Oct. 30 (Hea...ib shows promise for treating people with what,s k...er -- a group of patients who typically have a poo... and 3. , As reported in the November issue of T...
...bariatric surgeries to high-volume centers disprop...red patients, populations which are among the most...rn Medical Center researchers shows. , Government...d because some studies have identified better outc...
...E: STE ) today announced financial results for it...007. Fiscal 2008 second quarter revenues,increased... in the second,quarter of fiscal 2007, primarily d...d with net income of $16.4 million, or $0.25 per,d...
...daq(R) Technologies Inc.,(TSX: NDQ), a developer o...ed,therapies for the operating room, will host a c...ancial results for the third quarter ended Septemb...lay: 416-640-1917 or 1-877-289-8525 (Available ...
...ink Sheets: HRAL) announced that it has received a...owned subsidiary of Wal-Mart International, Inc.,(...g-aid clinics in two,Toronto area Wal-Mart Stores.... will both officially open today. This,expansion i...
Other Medicine News:Health News:New Drug Promising Against Tough-to-Treat Kidney Cancer 2Health News:Government restrictions on weight loss surgeries limit access for poor, underinsured patients 2Health News:Government restrictions on weight loss surgeries limit access for poor, underinsured patients 3Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 2Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 3Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 4Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 5Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 6Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 7Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 8Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 9Health News:STERIS Corporation Announces Fiscal 2008 Second Quarter Results 10Health News:Novadaq announces third quarter 2007 conference call and webcast 2Health News:Novadaq announces third quarter 2007 conference call and webcast 3Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 2Health News:HearAtLast Continues Rapid Expansion, Opening Two New Retail Locations in Richmond Hill and Markham Wal-Mart Stores Number 3195 and 3053 3
(Date:11/25/2009)...wswire-FirstCall/ -- American Scientific Resources...ed to announce that they have opened a regional ma...ai, China. ,, ASR has been able to secure a loc...he development and production of current and futur...ts to be distributed and sold globally. Currently...
(Date:11/25/2009)...wire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS...ted to discovering, developing and commercializing...inancial results for the fiscal year ended Septemb... $58.4 million in cash, cash equivalents and short...9 Highlights ,, RG7128 ,, Phase 2b Tria...
(Date:11/25/2009)... -- BioTrends Research Group, Inc. released Wave 1...the first in a multi-phase syndicated market resea...Biotech,s Stelara, from product launch through the...he report provides quantitative information from 7...n from a subset of 20. The reports assess trial a...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Pharmasset Reports Fiscal Year End 2009 Financial Results 9Pharmasset Reports Fiscal Year End 2009 Financial Results 10Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Reminder 3A Transgenomic Inc Announces Second Quarter 2009 Earnings Release Conference Call Webcast 13529 1Reminder 3A Transgenomic Inc Announces Second Quarter 2009 Earnings Release Conference Call Webcast 13529 2VJ Day marked with launch of POW project on Merseyside 54315 1VJ Day marked with launch of POW project on Merseyside 54315 2Hebrew U researchers shed light on the brain mechanism responsible for processing of speech 9543 1Hebrew U researchers shed light on the brain mechanism responsible for processing of speech 9543 2
... IIa Clinical Trial in Type 2,Diabetes Patients An...all/ - Transition,Therapeutics Inc. ("Transition")...y Phase IIa clinical trial indicating that 4-weeks...1-I.N.T.(TM), showed,sustained reductions in blood...A1C (HbA1c), for 6 months post-treatment. The type...
...-(BUSINESS WIRE)--Jun 28, 2007,- Progenics Pharmac...icals, a division of Wyeth (NYSE: WYE), today anno...el extension study of,subcutaneous methylnaltrexon... (OIC) in patients with advanced illness. The resu...onal Association of,Supportive Care in Cancer (MAS...
Other Medicine Technology:A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 2A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 3A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 4A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 2Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 3Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 4Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 6
VS-1/IS-1 Plug
Universal Adaptor Sleeve
Silicone - End Caps
...biatrial stimulation. This is the first implant fo...s. The patients benefit from a lasting improvement...ainst cardiac remodeling. Tupos LA uses biatrial s...ptomatic and medicine resistant atrial tachycardia...
Medicine Products: